GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
Investor insights
Funding rounds participated in
$157M sweet spot round size
Investor type
Basic info
Industry
Sectors
Date founded
2020
Funding rounds raised
Total raised
$157M
from 2 investors over 1 rounds
GentiBio raised $157M on September 11, 2021
Investors: Matrix Capital Management and + 5 Other investors